Abstract
In November 2002, aripiprazole (Abilify; Otsuka/ Bristol-Myers Squibb), the first in a new class of atypical antipsychotics, was approved by the US FDA for the treatment of schizophrenia. Can it achieve the market success of the previous generation of atypical antipsychotics?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Waterborne aripiprazole blunts the stress response in zebrafish
Scientific Reports Open Access 22 November 2016
-
The potential for selective pharmacological therapies through biased receptor signaling
BMC Pharmacology and Toxicology Open Access 13 August 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lewis, D. A. & Lieberman, J. A. Catching up on schizophrenia: natural history and neurobiology. Neuron 28, 325–334 (2000).
Yasuda, Y. et al. 7-[3-[4-(2,3 dimethylphenyl)piperazinyl] propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine receptor agonist and postsynaptic D2 receptor antagonist. Life Sci. 42, 1941–1954 (1988).
Kikuchi, T. et al. 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274, 329–336 (1995).
Oshiro, Y. et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J. Med. Chem. 41, 658–667 (1998).
Burris, K. D. et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381–389 (2002).
Jordan, S. et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol. 441, 137–140 (2002).
FDA Drug Approvals List [online] (cited 28 April 2003) <http://www.fda.gov/cder/foi/label/2002/21436_Abilify_lbl.pdf> (2002).
Kane, J. M. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63, 763–771 (2002).
Taylor, D. M. Aripiprazole: a review of its pharmacology and clinical use. Int. J. Clin. Pract. 57, 49–54 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grady, M., Gasperoni, T. & Kirkpatrick, P. Aripiprazole. Nat Rev Drug Discov 2, 427–428 (2003). https://doi.org/10.1038/nrd1114
Issue Date:
DOI: https://doi.org/10.1038/nrd1114
This article is cited by
-
Waterborne aripiprazole blunts the stress response in zebrafish
Scientific Reports (2016)
-
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Nature Reviews Drug Discovery (2013)
-
The potential for selective pharmacological therapies through biased receptor signaling
BMC Pharmacology and Toxicology (2012)
-
Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats
Psychopharmacology (2007)
-
Assays for enhanced activity of low efficacy partial agonists at the D2 dopamine receptor
British Journal of Pharmacology (2006)
